Fra-1 regulates vimentin during Ha-RAS-induced epithelial mesenchymal transition in human colon carcinoma cells

被引:58
作者
Andreolas, Chrysovalantis [1 ]
Kalogeropoulou, Margarita [1 ]
Voulgari, Angeliki [1 ]
Pintzas, Alexander [1 ]
机构
[1] Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, Lab Signal Mediated Gene Express, Athens 11635, Greece
关键词
RAS; vimentin; FRA-1; epithelial-mesenchymal transition;
D O I
10.1002/ijc.23309
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The process of epithelial mesenchymal transition, whereby cells acquire molecular alterations and fibroblastic features, is a fundamental process of embryogenesis and cancer invasion/metastasis. The mechanisms responsible for epithelial mesenchymal transition remain elusive. Human tumors frequently establish constitutively activated RAS signaling, which contributes to the malignant phenotype. In an effort to dissect distinct RAS isoform specific functions, we previously established human colon cell lines stably overexpressing activated Harvey-RAS (Ha-RAS) and Kirsten-RAS (Ki-RAS). Using these, we observed that only oncogenic Ha-RAS overexpression resulted in morphologic and molecular changes suggestive of epithelial to mesenchymal transition. We showed that vimentin, a key molecule of epithelial mesenchymal transition, was differentially regulated between Ha-RAS and Ki-RAS leading to a Ha-RAS specific induction of a migrative phenotype and eventually epithelial to mesenchymal transition. We demonstrated that the AP-1 sites in vimentin promoter could be involved in this regulation. A potential role of FRA-1 was suggested in the regulation of vimentin during the Ha-RAS-induced epithelial to mesenchymal transition, in association with colon cell migration. Our results therefore propose that in colon cells, the induction of epithelial mesenchymal transition by oncogenic Ha-RAS could occur through the overexpression of proteins like FRA-1 and vimentin. (c) 2007 Wiley-Liss, Inc.
引用
收藏
页码:1745 / 1756
页数:12
相关论文
共 41 条
[31]   Epithelial-mesenchymal transitions in tumour progression [J].
Thiery, JP .
NATURE REVIEWS CANCER, 2002, 2 (06) :442-454
[32]  
TIWARI G, MOL CANC RES, P475
[33]   Cellular integrity plus: organelle-related and protein-targeting functions of intermediate filaments [J].
Toivola, DM ;
Tao, GZ ;
Habtezion, A ;
Liao, J ;
Omary, MB .
TRENDS IN CELL BIOLOGY, 2005, 15 (11) :608-617
[34]   Distinct roles of Jun:Fos and Jun:ATF dimers in oncogenesis [J].
van Dam, H ;
Castellazzi, M .
ONCOGENE, 2001, 20 (19) :2453-2464
[35]   ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility [J].
Vial, E ;
Sahai, E ;
Marshall, CJ .
CANCER CELL, 2003, 4 (01) :67-79
[36]   Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells [J].
Vial, E ;
Marshall, CJ .
JOURNAL OF CELL SCIENCE, 2003, 116 (24) :4957-4963
[37]  
WARD KR, 2004, ODCOGENE, V23, P1197
[38]   c-Jun and the dominant-negative mutant, TAM67, induce vimentin gene expression by interacting with the activator Sp1 [J].
Wu, YZ ;
Zhang, XP ;
Zehner, ZE .
ONCOGENE, 2003, 22 (55) :8891-8901
[39]   Transactivation of Fra-1 and consequent activation of AP-1 occur extracellular signal-regulated kinase dependently [J].
Young, MR ;
Nair, R ;
Bucheimer, N ;
Tulsian, P ;
Brown, N ;
Chapp, C ;
Hsu, TC ;
Colburn, NH .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (02) :587-598
[40]   High levels of phosphorylated c-Jun, Fra-1, Fra-2 and ATF-2 proteins correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model [J].
Zoumpourlis, V ;
Papassava, P ;
Linardopoulos, S ;
Gillespie, D ;
Balmain, A ;
Pintzas, A .
ONCOGENE, 2000, 19 (35) :4011-4021